About Careers MedBlog Contact us

Generic Drugs for Attention Deficit Hyperactivity Disorder Faces Safety Concerns

by Julia Samuel on April 11, 2015 at 6:07 PM
Font : A-A+

Generic Drugs for Attention Deficit Hyperactivity Disorder Faces Safety Concerns

Concerta, the generic drug prescribed for Attention Deficit Disorder (ADD) had some side effects on patients. The Food and Drug Administration announced it had concerns about whether two approved generic versions of Concerta were in fact therapeutically equivalent to the name-brand drug.

"Two of these generics, so to speak, were not exactly providing the same rate and extent of absorption of medicine that Concerta had," explained Dr. Andrew Adesman of the Steven and Alexandra Cohen Children's Medical Center, New York.


The FDA said the generics are no longer recommended as an automatic substitute for Concerta though they have no serious safety issues and can still be prescribed, but they may not work as effectively.

In some patients, the FDA found generics manufactured by Mallinckrodt and Kudco may deliver their dosage at a slower rate, lowering effectiveness. Concerta's manufacturer, Janssen, another version of the drug had no such problems.

Source: Medindia


Recommended Reading

Latest Drug News

 India's First Urinary Incontinence Drug Launched
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
 New Ray of Hope for Atrial Fibrillation Patients With Kidney Disease
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Anti-viral Drug Bulevirtide Helps Treat Chronic Hepatitis D
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Price Cap Move Will Place Eli Lilly Strongly in Insulin Market
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Generic Drugs for Attention Deficit Hyperactivity Disorder Faces Safety Concerns Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests